A Biomarker Study Using Tumor-infiltrating Regulatory T Cells to Predict the Efficacy to Immune Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer and Malignant Melanoma
Not Applicable
Suspended
- Conditions
- on-Small Cell Lung Cancer or Malignant Melanoma
- Registration Number
- JPRN-UMIN000044535
- Lead Sponsor
- Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Hematology, Oncology and Respiratory Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine whether assessment of tumor-infiltrating PD-1 positive regulatory T cells (Treg) can be a predictive biomarker of ICI efficacy.
- Secondary Outcome Measures
Name Time Method To determine whether other assessments in tumor-infiltrating T lymphocytes (TIGIT, LAG-3, CTLA-4, or other) are predictive biomarkers of ICI efficacy.